IVS Director, Dr. Daniel Salmon, and co-authors discuss vaccine pharmacovigilance programs and make recommendations on how to fund and improve safety systems into the future. The recently published article, Lessons Learned from COVID-19, H1N1, and Routine Vaccine Pharmacovigilance in the United States: A Path to a More Robust Vaccine Safety Program, describes the key characteristics of vaccine pharmacovigilance programs, reviews U.S. vaccine pharmacovigilance for routine vaccination programs, COVID-19, and H1N1, and makes recommendations for improving future vaccine safety systems.
Institute for Vaccine Safety
Johns Hopkins Bloomberg School of Public Health
615 N Wolfe Street
Baltimore, MD 21205
USA
info@vaccinesafety.edu
All rights reserved.